EMBECTA CORP. Related Parties Amount in Cost of Sales
EMBECTA CORP. (EMBC) reported Related Parties Amount in Cost of Sales of $0 for the 12-month period ending 2023-09-30, per its 10-K filed 2023-11-29.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RelatedPartiesAmountInCostOfSales · last filed 2023-11-29
- EMBECTA CORP. related parties amount in cost of sales for the quarter ending 2022-09-30 was $5.90M, a 42.16% decline year-over-year.
- EMBECTA CORP. related parties amount in cost of sales for the quarter ending 2022-06-30 was $0.00, a 100.00% decline year-over-year.
- EMBECTA CORP. related parties amount in cost of sales for the quarter ending 2022-03-31 was $10.60M, a 6.00% increase year-over-year.
- EMBECTA CORP. related parties amount in cost of sales for the quarter ending 2021-12-31 was $11.50M, a 27.78% increase year-over-year.
- EMBECTA CORP. related parties amount in cost of sales for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- EMBECTA CORP. related parties amount in cost of sales for fiscal 2022 was $28.00M, a 31.03% decline from fiscal 2021.
- EMBECTA CORP. related parties amount in cost of sales for fiscal 2021 was $40.60M, a 6.45% decline from fiscal 2020.
- EMBECTA CORP. related parties amount in cost of sales for fiscal 2020 was $43.40M.
| Period end | Related Parties Amount in Cost of Sales 3 month | Related Parties Amount in Cost of Sales 6 month | Related Parties Amount in Cost of Sales 9 month | Related Parties Amount in Cost of Sales 12 month |
|---|---|---|---|---|
| 2023-09-30 | $0.00 10-K · filed 2023-11-29 | |||
| 2022-09-30 | $5.90M derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-29 | $5.90M derived: sum of 2 quarters · filed 2023-11-29 | $16.50M derived: sum of 3 quarters · filed 2023-11-29 | $28.00M 10-K · filed 2023-11-29 |
| 2022-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-08-08 | $10.60M derived: sum of 2 quarters · filed 2023-08-08 | $22.10M 10-Q · filed 2023-08-08 | $32.30M derived: sum of 4 quarters · filed 2023-11-29 |
| 2022-03-31 | $10.60M 10-Q · filed 2023-05-12 | $22.10M 10-Q · filed 2023-05-12 | $32.30M derived: sum of 3 quarters · filed 2023-11-29 | $43.70M derived: sum of 4 quarters · filed 2023-11-29 |
| 2021-12-31 | $11.50M 10-Q · filed 2023-02-14 | $21.70M derived: sum of 2 quarters · filed 2023-11-29 | $33.10M derived: sum of 3 quarters · filed 2023-11-29 | $43.10M derived: sum of 4 quarters · filed 2023-11-29 |
| 2021-09-30 | $10.20M derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-29 | $21.60M derived: sum of 2 quarters · filed 2023-11-29 | $31.60M derived: sum of 3 quarters · filed 2023-11-29 | $40.60M 10-K · filed 2023-11-29 |
| 2021-06-30 | $11.40M 10-Q · filed 2022-08-15 | $21.40M derived: sum of 2 quarters · filed 2022-08-15 | $30.40M 10-Q · filed 2022-08-15 | |
| 2021-03-31 | $10.00M 10-Q · filed 2022-05-13 | $19.00M 10-Q · filed 2022-05-13 | ||
| 2020-12-31 | $9.00M 10-Q · filed 2022-03-16 | |||
| 2020-09-30 | $43.40M 10-K · filed 2022-12-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| Orthofix Medical Inc. (OFIX) | $0.373B | ||
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |